Streetbeat News

Analyst Ratings

SHOO

Telsey Advisory Group has reiterated its 'Market Perform' rating on Steven Madden (NASDAQ:SHOO) and maintained its price target of $39.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

APLS

JP Morgan analyst Anupam Rama has downgraded Apellis Pharmaceuticals from Overweight to Neutral and lowered the price target from $72 to $60.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

PYPL

Canaccord Genuity analyst Joseph Vafi maintains a 'Buy' rating on PayPal Holdings (NASDAQ:PYPL) but has lowered the price target from $160 to $110.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

EOLS

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Evolus (NASDAQ:EOLS) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

HUBS

Piper Sandler analyst Brent Bracelin has reiterated a Neutral rating on HubSpot (NYSE:HUBS) and maintained a $520 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

TSXV:HITI

Stifel analyst Andrew Partheniou has initiated coverage on High Tide (TSXV:HITI) with a Buy rating and a price target of C$2.5.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

QTWO

Piper Sandler analyst Arvind Ramnani maintains an Underweight rating on Q2 Holdings (NYSE:QTWO) and raises the price target from $24 to $30.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

TRI

RBC Capital analyst Drew McReynolds has downgraded Thomson Reuters (NYSE:TRI) from Outperform to Sector Perform, while raising the price target from $135 to $139.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:42 pm

QRVO

Exane BNP Paribas analyst Karl Ackerman has upgraded Qorvo (NASDAQ:QRVO) from Neutral to Outperform and set a price target of $135.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:41 pm

DOCS

Piper Sandler analyst Jessica Tassan has downgraded Doximity (NYSE:DOCS) from Overweight to Neutral and lowered the price target from $38 to $36.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 12:41 pm